CV NEWS FEED // The Biden administration has announced that it “strongly disagrees” with a federal appeals court’s Wednesday ruling that ended mail-order abortion pills and placed other restrictions on an abortion-causing drug.
“We strongly disagree with today’s ruling from the Fifth Circuit Court of Appeals in Alliance for Hippocratic Medicine v. FDA,” said White House Press Secretary Karine Jean-Pierre in a statement.
The Biden spokeswoman alleged that the court’s decision “undermines FDA’s scientific, independent judgment and reimposes onerous restrictions on access to safe and effective medication abortion.”
Due to the Supreme Court’s stay, mifepristone remains broadly available for now. But if the Fifth Circuit’s ruling stands, it will significantly roll back the ability for women in every state to get the health care they need, and undermine FDA’s scientific, evidence-based process for approving safe and effective medications that patients rely on.
She also claimed the lawsuit posed “an unprecedented threat to the FDA’s authority to review, approve, and set evidence-based requirements for a wide range of safe and effective drugs.”
Jean-Pierre confirmed that Biden’s Department of Justice “will be seeking Supreme Court review of the Fifth Circuit’s contrary decision.”
The Biden administration “will continue to stand by FDA’s independent approval of mifepristone as safe and effective,” she concluded. “In the face of these unprecedented attacks on women’s health, we will continue to fight for women’s freedom to make decisions about their own bodies.”
CatholicVote’s Director of Governmental Affairs Tom McClusky responded to the White House’s strong words.
“This death drug is at the centerpiece of the abortion agenda,” McClusky said, referring to mifepristone. “Which is why Democrats coerced the FDA over the years, including when Joe Biden was vice president, to cover up the health problems to women caused by injecting it into their bodies.”
“The White House fears that if the law prevails and the harmful drug is taken off the market, it would result in more babies being born,” McClusky added.
As CatholicVote reported Wednesday, the Fifth Circuit decision did allow mifepristone to “remain authorized by the Food and Drug Administration (FDA),” a decision that was criticized by Judge James Ho in his dissent.
CNBC listed the various restrictions the court’s ruling placed on mifepristone:
If the Supreme Court upholds Wednesday’s ruling, women would no longer be able to obtain the abortion pill through telemedicine appointments and by mail. Patients would have to receive a prescription from a doctor and have three follow-up appointments in person.
The restrictions would also shorten the time period when women can take the pill to 49 days into their pregnancy, down from 70 days.